Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Net Income (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Net Income for 7 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income changed N/A to $43.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.7 million, a N/A change, with the full-year FY2025 number at $20.9 million, up 111.88% from a year prior.
  • Net Income was $43.4 million for Q4 2025 at Soleno Therapeutics, up from $24.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $43.4 million in Q4 2025 to a low of -$43.8 million in Q1 2025.